Therapeutic targeting of differentiation-state dependent metabolic vulnerabilities in diffuse midline glioma
2024 · Nature Communications · 17 citations
https://doi.org/10.1038/s41467-024-52973-4
C
Chan Chung
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
144
Papers
1.8K
Citations
20
h-index
24
i10-index
Chan Chung is an academic researcher from Daegu Gyeongbuk Institute of Science and Technology. The author has contributed to research in topics: Glioma Diagnosis and Treatment & Cancer, Hypoxia, and Metabolism & ATP Synthase and ATPases Research. The author has an h-index of 20, co-authored 123 publications.
ORCID: 0000-0003-0510-8996Papers by this author
worksP4.11E.28 Pharmacological Comparison of Dostarlimab and Pembrolizumab in Metastatic Non-Small Cell Lung Cancer in PERLA
2024 · Journal of Thoracic Oncology · 1 citations
https://doi.org/10.1016/j.jtho.2024.09.741
Table S16 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways
2024 · 0 citations
https://doi.org/10.1158/2159-8290.27026252.v1
Table S2 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways
2024 · 0 citations
https://doi.org/10.1158/2159-8290.27026249
Supplementary Figures 1-15 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways
2024 · 0 citations
https://doi.org/10.1158/2159-8290.27026276.v1
Table S12 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways
2024 · 0 citations
https://doi.org/10.1158/2159-8290.27026264.v1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat